TrialNature communications2025

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.

Christian J Maine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.